What is TearClear?
TearClear is pioneering a novel approach to topical medication delivery for ocular surface applications. The company's core innovation lies in its platform designed to capture preservatives before they reach the ocular surface, aiming to enhance patient safety and compliance. Its lead product candidates are focused on glaucoma, with plans to expand into multiple future indications. This strategic positioning in the ophthalmic pharmaceutical sector underscores a commitment to addressing unmet needs in eye care.
How much funding has TearClear raised?
TearClear has raised a total of $26.5M across 2 funding rounds:
Series A
$4.5M
Series B
$22M
Series A (2017): $4.5M with participation from Visionary Venture Fund and Bluestem Capital
Series B (2020): $22M led by Bluestem Capital Company, Falcon Vision, Flying L Partners, and Visionary Ventures
Key Investors in TearClear
Visionary Venture Fund
Visionary Venture Fund is an investment firm specializing in ventures within the life sciences and ophthalmology sectors, leveraging strategic insights to support promising startups.
Bluestem Capital
Bluestem Capital is a venture capital firm focused on private equity investments, particularly in the Midwest, aiming to support and grow companies within its portfolio.
Visionary Ventures
Visionary Ventures is a venture capital firm that focuses on life sciences and ophthalmology startups, utilizing a network of experts to identify companies addressing unmet medical needs.
What's next for TearClear?
The recent major strategic investment signifies a critical growth phase for TearClear, likely enabling the company to advance its glaucoma product candidates through clinical trials and scale its proprietary drug delivery platform. This enterprise-level backing suggests confidence from investors in TearClear's technology and market potential. Future developments will likely focus on regulatory approvals, commercialization strategies, and potential expansion into other ophthalmic indications, solidifying its disruptive role in the pharmaceutical landscape.
See full TearClear company page
